Merck no longer expects April approval for surgery drug sugammadex after FDA cancels meeting

March 13, 2015 9:09 PM

3 0

WHITEHOUSE STATION, N.J. – Drugmaker Merck & Co. no longer expects its experimental injection sugammadex to be approved next month after another regulatory setback.

The company said Friday that the Food and Drug Administration has canceled a March 18 meeting to review sugammadex, which is designed to help patients "wake up" after surgical anesthesia, to do additional inspections of sites in a trial of hypersensitivity reactions with the drug. The FDA cancelled ...

Also read: UPDATE 1-Industrial equipment hire firm Ashtead hikes annual results forecast

Read more

To category page

Loading...